Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, 4D Molecular Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") virtually via the internet. On April 20, 2026, the record date for the meeting, there were 52,274,735 shares of the Company's common stock outstanding with each such share being entitled to one vote per share.

At the Annual Meeting, 44,038,022 shares of the Company's common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement").

Proposal 1. The Company's stockholders elected by a plurality of votes cast the Class III director nominees below to the Company's Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected.

Proposal 2. The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

Proposal 3. The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.